Do we need a Netflix for antibiotics?

More countries must provide the right incentives to develop drugs to combat antibiotic resistance. The FT's Andrew Jack explores the trend to tackle a growing global health threat by de-linking incentive payments to pharmaceutical companies from sales, offering pharma companies guaranteed income for innovative treatments